Q1 2024 · 13F-HR
Bain Capital Life Sciences Investors, LLCholdings as filed
Filed 2024-05-15 · accession 0000950123-24-005471
$1.24B
Reported value
26
Positions
2024-03-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| N62509109 | NAMS | NEWAMSTERDAM PHARMA COMPANY | $247.7M | 19.9% | 10,473,913 | Common | SOLE |
| 670703107 | NUVL | NUVALENT INC | $202.5M | 16.3% | 2,697,267 | Common | SOLE |
| 252828108 | DNTH | DIANTHUS THERAPEUTICS INC | $89.8M | 7.21% | 2,992,028 | Common | SOLE |
| 254604101 | IRON | DISC MEDICINE INC | $82.0M | 6.59% | 1,317,213 | Common | SOLE |
| 501976104 | KYTX | KYVERNA THERAPEUTICS INC | $78.6M | 6.32% | 3,163,868 | Common | SOLE |
| N69605108 | PHVS | PHARVARIS N V | $76.3M | 6.14% | 3,303,381 | Common | SOLE |
| 805111101 | SVRA | SAVARA INC | $72.5M | 5.83% | 14,565,457 | Common | SOLE |
| 03589W102 | ANNX | ANNEXON INC | $62.4M | 5.02% | 8,703,268 | Common | SOLE |
| 83422E204 | SLDB | SOLID BIOSCIENCES INC | $53.7M | 4.32% | 4,034,582 | Common | SOLE |
| 558868105 | MDGL | MADRIGAL PHARMACEUTICALS INC | $52.6M | 4.23% | 196,995 | Common | SOLE |
| 59045L106 | — | MERSANA THERAPEUTICS INC | $38.8M | 3.12% | 8,663,673 | Common | SOLE |
| 12674W109 | CABA | CABALETTA BIO INC | $27.6M | 2.22% | 1,617,364 | Common | SOLE |
| 98420X103 | ASNSUSD | X4 PHARMACEUTICALS INC | $23.5M | 1.89% | 16,915,784 | Common | SOLE |
| 87583X109 | TNGX | TANGO THERAPEUTICS INC | $23.0M | 1.85% | 2,892,663 | Common | SOLE |
| 03969K108 | ARQT | ARCUTIS BIOTHERAPEUTICS INC | $19.9M | 1.60% | 2,011,687 | Common | SOLE |
| 67080M103 | NRIX | NURIX THERAPEUTICS INC | $16.6M | 1.34% | 1,132,397 | Common | SOLE |
| 87184Q206 | SYRS | SYROS PHARMACEUTICALS INC | $14.7M | 1.18% | 2,749,808 | Common | SOLE |
| 56854Q200 | MRNS* | MARINUS PHARMACEUTICALS INC | $12.6M | 1.01% | 1,393,380 | Common | SOLE |
| 04683R106 | AVIR | ATEA PHARMACEUTICALS INC | $10.0M | 0.81% | 2,485,638 | Common | SOLE |
| 12529R107 | CCCC | C4 THERAPEUTICS INC | $9.3M | 0.75% | 1,142,210 | Common | SOLE |
| 75340L104 | RPID | RAPID MICRO BIOSYSTEMS INC | $8.2M | 0.66% | 8,434,560 | Common | SOLE |
| 00534A102 | IVVD | INVIVYD INC | $8.0M | 0.64% | 1,799,595 | Common | SOLE |
| 63909J108 | NAUT | NAUTILUS BIOTECHNOLOGY INC | $5.9M | 0.47% | 2,000,000 | Common | SOLE |
| 00461U105 | ACRS | ACLARIS THERAPEUTICS INC | $3.7M | 0.30% | 3,000,000 | Common | SOLE |
| 98422T100 | — | XILIO THERAPEUTICS INC | $3.0M | 0.24% | 2,805,413 | Common | SOLE |
| N62509117 | NAMSW | NEWAMSTERDAM PHARMA COMPANY | $1.1M | 0.09% | 100,000 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.